Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib

The Bruton tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding. Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side effects of ibrutinib. The second-generation Btk inhibitor acalabrutinib was developed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Bye, Alexander P., Unsworth, Amanda J., Desborough, Michael J., Hildyard, Catherine A. T., Appleby, Niamh, Bruce, David, Kriek, Neline, Nock, Sophie H., Sage, Tanya, Hughes, Craig E., Gibbins, Jonathan M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728643/
https://ncbi.nlm.nih.gov/pubmed/29296914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017011999
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados